ALD

Lightwave Logic Acquires Polymer Technology and Intellectual Property Assets of Chromosol Ltd (UK)

Retrieved on: 
Tuesday, November 29, 2022
Marketing, EO, Environment, Programmable interrupt controller, PIC, PDK, Engineering, Silicon, Kurdistan, LightWave 3D, ALD, Temperature, Patent, Logic, Telecommunication, Risk, Intellectual property, Polymer, Form 10-K, Acquisition, 3D printing, Instrumentation, EU

ENGLEWOOD, Colo., Nov. 29, 2022 /PRNewswire/ -- Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic polymers to transmit data at higher speeds with less power, today announced that it has acquired the polymer technology and intellectual property assets of Chromosol Ltd (UK).

Key Points: 
  • ENGLEWOOD, Colo., Nov. 29, 2022 /PRNewswire/ -- Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic polymers to transmit data at higher speeds with less power, today announced that it has acquired the polymer technology and intellectual property assets of Chromosol Ltd (UK).
  • Dr. Michael Lebby, Chief Executive Officer of Lightwave Logic, said: "Chromosol's' polymer technology and intellectual property patent dovetails well with Lightwave Logic's development of a polymer platform that not only enables 'green photonics' but is foundry compatible with manufacturing PDKs.
  • "What is more interesting is that every foundry we have visited has ALD systems and equipment in place for semiconductor processing.
  • Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated.

ALD: Announcement

Retrieved on: 
Tuesday, November 29, 2022
Rights issue, Euronext Paris, Société Générale, LeasePlan, EuroLeague Final Four, Rights, ALD, Prospectus, Exercise, ISIN, Segment, Sale, Regulatory News Service, Risk, Acquisition, AMF, Security (finance), Medical device, Euronext

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The Rights Issue will enable ALD to finance a portion of the Acquisition price, which amounts to 4.5 billion [1] .
  • As of the date of this press release, and as stated on November 28th, 2022 main regulatory and all expected anti-trust conditions precedent have been completed.
  • The Acquisition is expected to close in Q1 2023 subject to remaining regulatory approvals and other customary closing conditions [3] .

Forge Nano Ranks Among Fastest-Growing Companies in North America on the 2022 Deloitte Technology Fast 500™

Retrieved on: 
Wednesday, November 16, 2022
Infection, Growth, Electronics, Atomic layer deposition, ALD, Creativity, Science and technology in Asia, 175th Infantry Regiment (United States), Telecommunication, Deloitte Technology Fast 500, Renewable energy

DENVER, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Forge Nano, a leading materials science company, today announced it ranked 175th on the Deloitte Technology Fast 500 , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year.

Key Points: 
  • DENVER, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Forge Nano, a leading materials science company, today announced it ranked 175th on the Deloitte Technology Fast 500 , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year.
  • Overall, 2022 Technology Fast 500 companies achieved revenue growth ranging from 241% to 125,138% from 2018 to 2021, with median growth of 611%.
  • For more information, visit www.ForgeNano.com
    Now in its 28th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies both public and private in North America.
  • Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

Atomic Layer Deposition Market Report 2022: Growing Demand for Electric Vehicles Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022
Chemicals, Plastics, Manufacturing, Partnership, Government, USD, Research, Electronics, Semiconductor, Growth, World Economic Forum, COVID-19, ALD, Tissue engineering, Tokyo Electron, Coal, Lithium

The global atomic layer deposition market is expected to reach USD 4.7 billion by 2030, registering a CAGR of 12.3% from 2022 to 2030, Atomic layer deposition (ALD) market growth is significantly driven by the increasing semiconductor fabrication for chip production across the world.

Key Points: 
  • The global atomic layer deposition market is expected to reach USD 4.7 billion by 2030, registering a CAGR of 12.3% from 2022 to 2030, Atomic layer deposition (ALD) market growth is significantly driven by the increasing semiconductor fabrication for chip production across the world.
  • Atomic layer deposition used in semiconductor chip fabrication allows the deposition of molecules at a specific space with utmost uniformity.
  • Growing demand for electric vehicles and increasing research and development is expected to fuel the market growth.
  • Growing government spending and rising research and development activities are expected to drive the use of atomic layer deposition during the forecast period.

Atomic Layer Deposition Global Market to Reach $4.7 Billion by 2030 at a 12.3% CAGR

Retrieved on: 
Friday, November 18, 2022
Growth, Tokyo Electron, Tissue engineering, Government, Semiconductor, Partnership, ALD, Research, Electronics, World Economic Forum, COVID-19, USD, Renewable energy, Lithium

The global atomic layer deposition market is expected to reach USD 4.7 billion by 2030, registering a CAGR of 12.3% from 2022 to 2030, Atomic layer deposition (ALD) market growth is significantly driven by the increasing semiconductor fabrication for chip production across the world.

Key Points: 
  • The global atomic layer deposition market is expected to reach USD 4.7 billion by 2030, registering a CAGR of 12.3% from 2022 to 2030, Atomic layer deposition (ALD) market growth is significantly driven by the increasing semiconductor fabrication for chip production across the world.
  • Atomic layer deposition used in semiconductor chip fabrication allows the deposition of molecules at a specific space with utmost uniformity.
  • Atomic layer deposition is gaining popularity in the medical industry with increasing research and development.
  • Growing government spending and rising research and development activities are expected to drive the use of atomic layer deposition during the forecast period.

Mass-Vac Introduces MV PosiTrap® Vacuum Inlet Traps that Help Prevent Premature Pump Failures

Retrieved on: 
Tuesday, November 15, 2022
University, OEM, Acid, Polypropylene, MV, CFM, Hydrogen peroxide, Stainless steel, ISO, ALD, NW, Hydraulic machinery

NORTH BILLERICA, Ma., Nov. 15, 2022 /PRNewswire-PRWeb/ -- Mass-Vac, Inc. has introduced a line of vacuum pump inlet traps that are designed to be incorporated into systems and equipment used in small research laboratories and universities.

Key Points: 
  • MV PosiTrap Vacuum Inlet Traps feature a fully positive seal at both ends to prevent contaminants from being ingested into the pump which can cause premature pump failure and come in 4" and 8" sizes for pumps up to 25 and 50 CFM, respectively.
  • Designed to protect pumps from particulates, organic solvents, hydrogen peroxide, acids, and water vapor, filter media offered for MV PosiTrap Vacuum Inlet Traps include stainless steel mesh, activated charcoal, molecular sieve, polypro in 20-0.1 micron pore size and Sodasorb.
  • Typical applications include ALD tools, freeze- and gel dryers, rotary evaporators, vacuum ovens, glove boxes, mass spectrometers, and vacuum sterilizers.
  • MV PosiTrap Vacuum Inlet Traps are priced from $325.00 (list), depending upon configuration and the selected filter cartridges.

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Retrieved on: 
Monday, November 7, 2022
GLOBE, FLS, Plasma, Institute of Liver and Biliary Sciences, FXR, OCA, ALD, Intercept, Nasdaq, NASH, Safety, Research, Gene, Association, Population, AASLD, American Association for the Study of Liver Diseases, Development, SAH, Chronic liver disease, Half-life, Mortality, FRESH, MAD, PBC, Intercept Pharmaceuticals, SAD, Patient, Wireless ambulatory ECG, Liver transplantation, Pharmacokinetics, Vital signs, American Association, Disease, Research and development, Female, Absorption, Liver, Alcoholic liver disease, Urine, Therapy, Primary biliary cholangitis, Male, Fatty liver disease, Pharmaceutical industry, Dietary supplement, Vaccine, Company

MORRISTOWN, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) --  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced plans to focus development of its next-generation FXR agonist, INT-787, in severe alcohol-associated hepatitis (sAH). Alcohol-related liver disease is currently the leading indication for liver transplant listing in the U.S., with a marked increase in patients with sAH needing liver transplantation. Currently, there are no medicines with an approved indication to treat sAH.

Key Points: 
  • The company has also initiated the FRESH (FXR Effect on Severe Alcohol-Associated Hepatitis) study, a Phase 2a trial evaluating the safety, tolerability, efficacy and pharmacokinetics of INT-787 in subjects with sAH.
  • Patients with severe alcohol-associated hepatitis (sAH) are now younger, with an increased representation of females compared to past decades, reflecting changing patterns of alcohol consumption in the U.S.
  • Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH).
  • This press release contains forward-looking statements (FLS), including regarding our product pipeline, our clinical studies, and our research and development (R&D) plans.

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022

Retrieved on: 
Tuesday, November 8, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Food, Plasma, Prescription, Adrenoleukodystrophy, VLCFA, TZD, ALD, Growth, Fibrosis, FDA, Patient, Association, Company, MD, Biomarker, Serono, NASH, Merck Serono, AMN, ODD, Clinical trial, Orphan, Institute of Liver and Biliary Sciences, American Association, ADPKD, Disease, Fatty liver disease, POC, IPF, American Association for the Study of Liver Diseases, Non-alcoholic fatty liver disease, USD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Histology, Merck, Autosomal dominant polycystic kidney disease, Magnetic resonance imaging, Human, JPY, Degenerative disease, Edema, Pioglitazone, EUR, IRIS, Safety, AASLD, Male, Pharmacokinetics, Type 2 diabetes, Pharmaceutical industry, Euronext, Imeglimin

The royalty stream from TWYMEEGs growth is poised to deliver significant value to Poxel, noted Thomas Kuhn, Chief Executive Officer of Poxel.

Key Points: 
  • The royalty stream from TWYMEEGs growth is poised to deliver significant value to Poxel, noted Thomas Kuhn, Chief Executive Officer of Poxel.
  • This is an important milestone for Poxel, but also more broadly for NASH, for which there is still no approved treatment.
  • Based on these results, we are prioritizing PXL065 in NASH and are actively looking for a partner to advance its development.
  • Third Quarter and Nine Months Ended September 30, 2022 Cash and Revenue
    As of September 30, 2022, total cash and cash equivalents were EUR 17.1 million (USD 16.6 million), as compared to EUR 16.1 million at June 30, 2022.

Poxel Announces Upcoming Participation at the Jefferies London Healthcare Conference

Retrieved on: 
Monday, November 7, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, ALD, Euronext Paris, Company, Degenerative disease, NASH, ADPKD, Fatty liver disease, Forward-looking statement, Adenosine, AMPK, Adrenoleukodystrophy, Partnership, Conference, Fine chemical, Euronext, Imeglimin

POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the Jefferies London Healthcare Conference, to be held in London from Tuesday, November 15 to Thursday, November 17, 2022.

Key Points: 
  • POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the Jefferies London Healthcare Conference, to be held in London from Tuesday, November 15 to Thursday, November 17, 2022.
  • Members of the Poxel management team will be available for one-on-one meetings with investors.
  • Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

ALD: Third quarter 2022 Results

Retrieved on: 
Monday, November 7, 2022
Face, Central bank, Professional, Ministry, Growth, LeasePlan, EUR, Ministry of Finance (Chile), Income, Total, Legislation, Regulatory News Service, Central Bank of Russia, NET, EV, UCS, Electric vehicle, OF, Acquisition, ALD, Depreciation, Security (finance), Film, Jet fuel, Renewable energy, Risk management, Holding company, Real estate, Semiconductor, Euro, FFM, Lease

Against this background and in view of the outstanding results recorded in 9M 2022, ALD is upgrading its guidance for the full year 2022 as follows:

Key Points: 
  • Against this background and in view of the outstanding results recorded in 9M 2022, ALD is upgrading its guidance for the full year 2022 as follows:
    ALD expects the used car market to remain strong at least until the end of the year.
  • Notwithstanding, the reduction in depreciation costs [1] recorded since H1 2022 (increasing the Leasing contract margin) anticipated part of expected future UCS results.
  • UCS result reached EUR 3,014 per unit in Q3 2022, down from EUR 3,330 per unit in Q2 2022.
  • ALD sold 198 thousand units [9] in 9M 2022, of which 63 thousand units in Q3 2022, vs 247 thousand in 9M 2021.